Compare GORO & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GORO | PLX |
|---|---|---|
| Founded | 1998 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.5M | 168.4M |
| IPO Year | 2010 | 1996 |
| Metric | GORO | PLX |
|---|---|---|
| Price | $1.29 | $2.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $1.63 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 2.7M | 649.1K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.80 | N/A |
| EPS | 0.03 | ★ 0.22 |
| Revenue | ★ $99,759,000.00 | $52,744,000.00 |
| Revenue This Year | $25.99 | $36.81 |
| Revenue Next Year | $5.78 | N/A |
| P/E Ratio | $43.67 | ★ $10.77 |
| Revenue Growth | ★ 51.78 | N/A |
| 52 Week Low | $0.43 | $1.36 |
| 52 Week High | $1.87 | $3.19 |
| Indicator | GORO | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 50.52 | 69.03 |
| Support Level | $1.22 | $2.06 |
| Resistance Level | $1.47 | $2.66 |
| Average True Range (ATR) | 0.08 | 0.09 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 48.74 | 98.36 |
Gold Resource Corp is a producer of metal concentrates that contain gold, silver, copper, lead, and zinc in Oaxaca, Mexico. . It targets low capital expenditure projects with the potential for generating high returns on capital. The company's two pipeline projects are; Don David Gold at Oaxaca, Mexico, and Back Forty at Michigan, United States of America. The Company has two reporting segments, based on geographic regions. Oaxaca, Mexico represents the Companies only operating segment with a production stage property. The Companies other reporting segment is Michigan, U.S.A., with an exploration stage property.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.